Opinion: Ultomiris: Can drug innovation be too expensive?
Do modifications that reduce how often a drug must be administered qualify for substantial patent protection? Or should patent exclusivity be awarded only to drugs that lead to better outcomes?
When it comes to new drugs, how much are we willing to pay for innovation? That question, touched on by Craig Garthwaite and Benedic Ippolito in their First Opinion on drug prices, deserves a deeper look.
A new biologic drug, Ultomiris, made by Alexion Pharmaceuticals, is a prime example of innovation that may be too expensive.
The Food and Drug Administration , a, an inherited disease in which the body’s immune system destroys its healthy red and white blood cells and platelets.
